← Leaderboards
David S. Hong
University Of Tx Md Anderson Can Ctr
$3,694,798
Attributed
$6,904,044
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,904,044 · 4
By mechanism
R01$3,457,397 · 2
K12$2,037,821 · 1
P30$1,408,826 · 1
Top collaborators
- Scott Kopetz8 shared
- Goldy C George6 shared
- Shannon Neville Westin3 shared
- Tito R Mendoza2 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Scott Kopetz$13,199,822
- Ronald Anthony Depinho$97,148,322
- Ahmed Kaseb$3,699,074
- Goldy C George$776,699
- Sriram Yennu$3,268,567
Others in their field
Top investigators on “Cancer Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$366,127,178
- Norman Wolmark · Nsabp Foundation, Inc.$292,963,206
- Gregory H Reaman · National Childhood Cancer Foundation$271,061,526
- Peter C Adamson · National Childhood Cancer Foundation$269,808,480
- Charles A Coltman · Southwest Oncology Group$178,303,465
- Sudhir Raju · Ctis, Inc.$162,436,462
Research focus
Cancer TherapyClinical TrialsProgramsNew AgentsMonitorEventEnsurePhase I Clinical TrialsAftercareCombined Modality TherapySafetyMalignant NeoplasmsResearch PersonnelUniversity Of Texas M D Anderson Cancer CenterEarly Phase Clinical TrialCancer CenterDrug KineticsPhase 2 StudyNovel TherapeuticsPatient OrientedLaboratory ResearchPeer ReviewCancer CareFaculty
Grant awards (18)
Paul Calabresi Clinical Oncology Award$804,617
K12 · FY2025 · CA
12 Clinical and Translational Research Center$379,325
P30 · FY2025 · CA · contact PI
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy$218,645
R01 · FY2025 · CA
Paul Calabresi Clinical Oncology Award$569,799
K12 · FY2024 · CA
12 Clinical and Translational Research Center$356,721
P30 · FY2024 · CA · contact PI
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy$341,315
R01 · FY2024 · CA
Paul Calabresi Clinical Oncology Award$663,405
K12 · FY2023 · CA
12 Clinical and Translational Research Center$336,390
P30 · FY2023 · CA · contact PI
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy$146,757
R01 · FY2023 · CA
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy$358,680
R01 · FY2022 · CA
12 Clinical and Translational Research Center$336,390
P30 · FY2022 · CA · contact PI
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy$366,000
R01 · FY2020 · CA
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy$366,000
R01 · FY2019 · CA
Therapeutic Strategies for Patients With BRAF Mutant Colorectal Cancer$332,000
R01 · FY2018 · CA · contact PI
Therapeutic Strategies for Patients With BRAF Mutant Colorectal Cancer$332,000
R01 · FY2017 · CA · contact PI
Therapeutic Strategies for Patients With BRAF Mutant Colorectal Cancer$332,000
R01 · FY2016 · CA · contact PI
Therapeutic Strategies for Patients With BRAF Mutant Colorectal Cancer$332,000
R01 · FY2015 · CA · contact PI
Therapeutic Strategies for Patients With BRAF Mutant Colorectal Cancer$332,000
R01 · FY2014 · CA · contact PI